Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre

Blood Cancer Talks

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.

Here are the abstracts that were discussed:

Mantle Cell Lymphoma

1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180069.html

2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)

https://ash.confex.com/ash/2023/webprogram/Paper191921.html

Chronic Lymphocytic Leukemia

1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063

2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:

https://ash.confex.com/ash/2023/webprogram/Paper187128.html

Hodgkin Lymphoma

1. S1826 outcomes in older adults:

https://ash.confex.com/ash/2023/webprogram/Paper180114.html

Diffuse Large B-cell Lymphoma

1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180381.html

2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper177588.html